{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:56:52Z","timestamp":1787169412523,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nucleic acid amplification testing (NAT) for blood screening has been previously performed in some countries to determine NAT yields. The current study sought to explore the non-discriminating reactive NAT yields using individual-NAT (ID-NAT) and characteristics of HBV NAT yields through a 10-year retrospective analysis in Zhejiang, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood donations were analyzed using individual-NAT mode by the transcription-mediated amplification (TMA) method. Supplementary HBV serological tests were performed using chemiluminescent immunoassay, and HBV viral load assay was performed by real-time polymerase chain reaction. Follow-up studies were performed in partial donors with low HBV viral loads.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Non-discriminating reactive NAT yields and HBV NAT yields\u00a0varied\u00a0in different\u00a0years. The yields ranged from 853.73 per million to 2018.68 per million and 624.60 per million to 1669.50 per million, respectively. In the 476 NAT yields, 19 were probable window periods (WP), 33 probable occult hepatitis B virus infections (OBIs), 409 were confirmed OBIs and 15 were chronic HBV infections. ID-NAT results were categorized in four groups, and the findings showed that the levels of HBV DNA viral loads were different in the four different groups (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u2009275.02, p\u2009&lt;\u20090.01). HBV viral load distribution was significantly different between anti-HBs positive and anti-HBc positive samples (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200949.429, p\u2009&lt;\u20090.01). Notably, only 42.03% donors were NAT repeated positive in the 138 repeat donors\u2019 follow up tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NAT screening of blood donations can reduce the risk of transfusion-transmitted HBV infections. Positive proportions of anti-HBs and anti-HBc are correlated with the HBV viral load level. However, low level of viral load donors pose risks in HBV NAT assays, and show fluctuating state for HBV viral load and leads to non-repeated NAT results during follow up studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06468-y","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T21:36:14Z","timestamp":1627680974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characteristic of HBV nucleic acid amplification testing yields from blood donors in China"],"prefix":"10.1186","volume":"21","author":[{"given":"Danxiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"issue":"9859","key":"6468_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"1","key":"6468_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0928-4346(96)82012-3","volume":"5","author":"GL Xia","year":"1996","unstructured":"Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, Nan JH, Qi XQ. Prevalence of hepatitis B and C virus infections in the general Chinese population Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun. 1996;5(1):62\u201373.","journal-title":"Int Hepatol Commun."},{"issue":"5","key":"6468_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","volume":"23","author":"F Cui","year":"2017","unstructured":"Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy China. Emerg Infect Dis. 2017;23(5):765\u201372.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"6468_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","volume":"49","author":"G Raimondo","year":"2008","unstructured":"Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Crax\u00ec A, Donato F, Ferrari C, Gaeta GB, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"6468_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1046\/j.1537-2995.2003.00424.x","volume":"43","author":"R Biswas","year":"2003","unstructured":"Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43(6):788\u201398.","journal-title":"Transfusion"},{"key":"6468_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12879-016-1834-2","volume":"16","author":"Z Wang","year":"2016","unstructured":"Wang Z, Zeng J, Li T, Zheng X, Xu X, Ye X, Lu L, Zhu W, Yang B, Allain J, et al. Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen China. BMC Infect Dis. 2016;16:498.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"6468_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/j.1537-2995.2008.01701.x","volume":"48","author":"FB Hollinger","year":"2008","unstructured":"Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48(5):1001\u201326.","journal-title":"Transfusion"},{"issue":"1","key":"6468_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1423-0410.2012.01624.x","volume":"104","author":"R Charlewood","year":"2013","unstructured":"Charlewood R, Flanagan P. Ultrio and Ultrio Plus non-discriminating reactives: false reactives or not? Vox Sang. 2013;104(1):7\u201311.","journal-title":"Vox Sang"},{"issue":"2","key":"6468_CR9","first-page":"126","volume":"25","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, He H, Yan R, Tang X, Deng X, Xie S. Epidemiology of hepatitis B in Zhejiang province during 2005\u20132017. Chin J Vacci Immun. 2019;25(2):126\u201330.","journal-title":"Chin J Vacci Immun"},{"issue":"1","key":"6468_CR10","first-page":"6","volume":"18","author":"F Cui","year":"2012","unstructured":"Cui F, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Shun X. Vaccination Progress of Hepatitis B Vaccine and Epidemiology Changes of Carrying Rate of Hepatitis B Surface Antigen by Province in China, 1992\u20132006. Chin J Vacc Immun. 2012;18(1):6\u201313.","journal-title":"Chin J Vacc Immun"},{"issue":"7","key":"6468_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/vox.12553","volume":"112","author":"JW Kang","year":"2017","unstructured":"Kang JW, Seo JH, Youn KW, Seo YI, Huh K, Choi GR, Min HK, Oh DJ, Jo HJ, Kim JN. Use of supplemental anti-HBc testing of donors showing non-discriminating reactive results in multiplex nucleic acid testing. Vox Sang. 2017;112(7):622\u20137.","journal-title":"Vox Sang"},{"key":"6468_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12879-019-4215-9","volume":"19","author":"X Ye","year":"2019","unstructured":"Ye X, Li T, Shao W, Zeng J, Hong W, Lu L, Zhu W, Li C, Li T. Nearly half of Ultrio plus NAT non-discriminated reactive blood donors were identified as occult HBV\u00a0infection\u00a0in South\u00a0China. BMC Infect Dis. 2019;19:574.","journal-title":"BMC Infect Dis."},{"issue":"3","key":"6468_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tracli.2017.06.014","volume":"24","author":"D Candotti","year":"2017","unstructured":"Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus Clin Biol. 2017;24(3):189\u201395.","journal-title":"Transfus Clin Biol"},{"key":"6468_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jmv.20963","volume":"79","author":"WH Gerlich","year":"2007","unstructured":"Gerlich WH, Wagner FF, Chudy M, Harritshoj LH, Lattermann A, Wienzek S, Glebe D, Saniewski M, Sch\u00fcttler CG, Wend UC, et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol. 2007;79:32\u20136.","journal-title":"J Med Virol"},{"issue":"7","key":"6468_CR15","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/trf.12096","volume":"53","author":"JP Allain","year":"2013","unstructured":"Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritsh\u00f8j L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013;53(7):1405\u201315.","journal-title":"Transfusion"},{"issue":"6","key":"6468_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2008.02.016","volume":"48","author":"S Levicnik-Stezinar","year":"2008","unstructured":"Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008;48(6):1022\u20135.","journal-title":"J Hepatol"},{"issue":"6","key":"6468_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MOH.0b013e32834bac10","volume":"18","author":"JP Allain","year":"2011","unstructured":"Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol. 2011;18(6):461\u20136.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"6468_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tracli.2003.11.007","volume":"11","author":"JP Allain","year":"2004","unstructured":"Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol. 2004;11(1):18\u201325.","journal-title":"Transfus Clin Biol"},{"issue":"1","key":"6468_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biologicals.2009.10.015","volume":"38","author":"M El Ekiaby","year":"2010","unstructured":"El Ekiaby M, Lelie N, Allain JP. Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals. 2010;38(1):59\u201364.","journal-title":"Biologicals"},{"issue":"5","key":"6468_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1128\/JCM.00145-11","volume":"49","author":"X Zheng","year":"2011","unstructured":"Zheng X, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain PJ, Li C. Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol. 2011;49(5):1730\u20137.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"6468_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.transci.2013.08.005","volume":"49","author":"X Ye","year":"2013","unstructured":"Ye X, Yang B, Zhu W, Zheng X, Du P, Zeng J, Li C. Six-year pilot study on nucleic acid testing for blood donations in China. Transfus Apher Sci. 2013;49(2):318\u201322.","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"6468_CR22","first-page":"172","volume":"12","author":"J Dong","year":"2014","unstructured":"Dong J, Wu Y, Zhu H, Li G, Lv M, Wu D, Li X, Zhu F, Lv H. A pilot study on screening blood donors with individual-donation nucleic acid testing in China. Blood Transfus. 2014;12(2):172\u20139.","journal-title":"Blood Transfus"},{"issue":"6","key":"6468_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000457965","volume":"44","author":"H Safic Stanic","year":"2017","unstructured":"Safic Stanic H, Babic I, Maslovic M, Dogic V, Bingulac-Popovic J, Miletic M, Jurakovic-Loncar N, Vuk T, Strauss-Patko M, Jukic I. Three-year experience in NAT screening of blood donors for transfusion transmitted viruses in croatia. Transfus Med Hemother. 2017;44(6):415\u201320.","journal-title":"Transfus Med Hemother"},{"issue":"Suppl 1","key":"6468_CR24","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/S1386-6532(06)80010-7","volume":"36","author":"H Yugi","year":"2006","unstructured":"Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing-Japanese experience. J Clin Virol. 2006;36(Suppl 1):S56-64.","journal-title":"J Clin Virol"},{"issue":"3","key":"6468_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000446217","volume":"43","author":"A Heim","year":"2016","unstructured":"Heim A. Evaluation of the procleix ultrio elite assay and the panther-system for individual NAT screening of blood, hematopoietic stem cell, tissue and organ donors. Transfus Med Hemother. 2016;43(3):177\u201382.","journal-title":"Transfus Med Hemother"},{"issue":"7","key":"6468_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1046\/j.1537-2995.2001.41070878.x","volume":"41","author":"C Matsumoto","year":"2001","unstructured":"Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001;41(7):878\u201384.","journal-title":"Transfusion"},{"issue":"7","key":"6468_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1537-2995.2007.01276.x","volume":"47","author":"M Satake","year":"2007","unstructured":"Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47(7):1197\u2013205.","journal-title":"Transfusion"},{"issue":"2","key":"6468_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/gutjnl-2018-316490","volume":"68","author":"D Candotti","year":"2019","unstructured":"Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68(2):313\u201321.","journal-title":"Gut"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06468-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06468-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06468-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T21:38:44Z","timestamp":1627681124000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06468-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6468"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06468-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Blood Center of Zhejiang Province, China. All participants provided written informed consent. To ensure donor confidentiality, donors were anonymized through de-identification (through use of codes).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}